Plus therapeutics presents respect-lm clinical trial results for reyobiq™ in patients with leptomeningeal metastases

Presentation by trial principal investigator at the 2025 sno/asco cns metastases conference plus will also host an educational symposium with leading experts titled, “reimagining your approach to leptomeningeal metastases” houston, july 15, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces the oral presentation of its respect-lm clinical trial results and a sponsored educational symposium, at the upcoming sno/asco cns metastases conference on august 14-16, 2025, at the baltimore waterfront marriott hotel in baltimore, md.   “previously presented data from respect-lm was highly encouraging in both the safety profile and response signal in patients with leptomeningeal metastases or lm,” said michael rosol, ph.d.
PSTV Ratings Summary
PSTV Quant Ranking